NCT03319485进行中（未招募）不适用
A Pivotal Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Neuro System
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- InSightec
- 入组人数
- 92
- 试验地点
- 20
- 主要终点
- Responder Analysis
研究概览
简要总结
Evaluate the safety and efficacy of unilateral focused ultrasound pallidotomy using the ExAblate 4000 System in the management of dyskinesia symptoms or motor fluctuations for medication refractory, advanced idiopathic Parkinson's disease.
详细描述
The goal of this prospective, two-arm, sham-controlled, randomized, multi-center pivotal study is to evaluate the safety and efficacy of unilateral focused ultrasound pallidotomy using the ExAblate 4000 System in the management of dyskinesia symptoms or motor fluctuations for medication refractory, advanced idiopathic Parkinson's disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women, age 30 years and older.
- •Subjects who are able and willing to give informed consent and able to attend all study visits through 12 Months.
- •Subjects with a diagnosis of idiopathic PD by UK Brain Bank Criteria as confirmed by a movement disorder neurologist at the site.
- •Levodopa responsive as defined by at least a 30% reduction in MDS-UPDRS motor subscale in the ON vs OFF medication state.
- •MDS-UPDRS score of ≥ 20 in the meds OFF condition OR Motor complications of PD on optimum medical treatment .
- •Subjects should be on a stable dose of all PD medications for 30 days prior to study entry as determined by medical records.
- •Subject is able to communicate sensations during the ExAblate procedure.
- •Subjects on stable antidepressant medications for at least 3 months
排除标准
- •Hoehn and Yahr stage in the ON medication state of 3 or greater.
- •Presence of other central neurodegenerative disease suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer's disease.
- •Any suspicion that Parkinsonian symptoms are a side effect from neuroleptic medications.
- •Subjects who have had deep brain stimulation or a prior stereotactic ablation of the basal ganglia.
- •Presence of significant cognitive impairment using MMSE ≤
- •Unstable psychiatric disease, defined as active uncontrolled depressive symptoms, psychosis, delusions, hallucinations, or suicidal ideation.
- •Subjects with an active alcohol or drug dependency or history of drug/alcohol abuse within the past year
- •Subjects with unstable cardiac status
- •Severe hypertension (diastolic BP > 100 on medication).
- •Current medical condition resulting in abnormal bleeding and/or coagulopathy.
- •Receiving anticoagulant (e.g., warfarin) or antiplatelet (e.g., aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g., Avastin) within one month of focused ultrasound procedure.
- •Subjects with risk factors for intraoperative or postoperative bleeding as indicated by: platelet count less than 100,000 per cubic millimeter; a documented clinical coagulopathy; or INR coagulation studies exceeding the institution's laboratory standard
- •Patient with kidney disease or on dialysis.
- •Subjects with standard contraindications for MR imaging
- •Significant claustrophobia that cannot be managed with mild medication.
- •Subjects who weigh more than the upper weight limit of the MR scanner table and who cannot fit into the MR scanner.
- •Subjects who are not able or willing to tolerate the required prolonged stationary supine position during treatment.
- •History of intracranial hemorrhage, multiple strokes, or a stroke within past 6 months.
- •Subjects with a history of seizures within the past year.
- •Subjects with brain tumors.
- •Subjects with intracranial aneurysms requiring treatment or arterial venous malformations (AVMs) requiring treatment.
- •Are participating or have participated in another clinical trial in the last 30 days.
结局指标
主要结局
Responder Analysis
时间窗: Change in UDysRS and MDS-UPDRS Part III Motor Exam score from before treatment to 3 months following treatment
Responder is defined as the patient reaching a minimally clinically significant difference on: 1. UDysRS (this measures dyskinesia and their impact) OR 2. MDS-UPDRS Part III Motor Exam -Total score (this measures overall motor fluctuations).
次要结局
- Severity of Device and Procedure related complications(At the time of ExAblate Pallidotomy procedure)
研究者
研究点 (20)
Loading locations...
相似试验
进行中（未招募）
不适用
Bilateral Treatment of Medication Refractory Essential TremorEssential TremorNCT04112381InSightec51
已完成
不适用
Analgesic efficacy of Transversus abdominis plance block : Ultrasono-guided method vs. Laparoscopic guided method.KCT0001576Kyungpook National University Medical Center80
Unknown
1 期
IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.Kidney TumorRenal Cell CancerNCT01967407University of Magdeburg20
已完成
2 期
Study of ExAblate Focused Ultrasound Ablation of Breast CancerBreast CancerNCT01620359InSightec14
Unknown
不适用
Single v Dual-Operator Ultrasound Technique for Peripheral Vascular Access in the Emergency DepartmentPatients With Difficult Vascular Access.NCT02806180Sunnybrook Health Sciences Centre128